Enanta Pharmaceuticals (NASDAQ:ENTA) Stock Rating Upgraded by StockNews.com

Enanta Pharmaceuticals (NASDAQ:ENTA) was upgraded by equities researchers at StockNews.com from a “sell” rating to a “hold” rating in a research note issued to investors on Wednesday.

ENTA has been the subject of several other reports. JMP Securities lowered their target price on Enanta Pharmaceuticals from $23.00 to $22.00 and set a “market outperform” rating for the company in a research note on Tuesday. JPMorgan Chase & Co. dropped their price objective on shares of Enanta Pharmaceuticals from $12.00 to $11.00 and set an “underweight” rating on the stock in a research report on Thursday, February 8th. Finally, HC Wainwright decreased their price objective on shares of Enanta Pharmaceuticals from $28.00 to $27.00 and set a “buy” rating for the company in a research report on Tuesday. One research analyst has rated the stock with a sell rating, four have issued a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $19.00.

Enanta Pharmaceuticals Price Performance

Shares of Enanta Pharmaceuticals stock opened at $12.93 on Wednesday. The stock has a market capitalization of $273.55 million, a price-to-earnings ratio of -2.07 and a beta of 0.54. The business has a 50-day moving average of $14.85 and a 200 day moving average of $12.09. Enanta Pharmaceuticals has a 12 month low of $8.08 and a 12 month high of $28.25.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its quarterly earnings data on Wednesday, February 7th. The biotechnology company reported ($1.58) EPS for the quarter, missing the consensus estimate of ($1.18) by ($0.40). Enanta Pharmaceuticals had a negative net margin of 187.77% and a negative return on equity of 60.38%. The business had revenue of $18.00 million during the quarter, compared to analysts’ expectations of $22.74 million. Equities research analysts anticipate that Enanta Pharmaceuticals will post -4.9 earnings per share for the current year.

Institutional Investors Weigh In On Enanta Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Nisa Investment Advisors LLC increased its position in shares of Enanta Pharmaceuticals by 417.8% during the fourth quarter. Nisa Investment Advisors LLC now owns 2,827 shares of the biotechnology company’s stock worth $27,000 after purchasing an additional 2,281 shares in the last quarter. Clearstead Advisors LLC acquired a new position in Enanta Pharmaceuticals during the third quarter worth approximately $57,000. Quantbot Technologies LP boosted its holdings in shares of Enanta Pharmaceuticals by 2,300.0% in the third quarter. Quantbot Technologies LP now owns 7,200 shares of the biotechnology company’s stock valued at $80,000 after acquiring an additional 6,900 shares during the period. Sherbrooke Park Advisers LLC purchased a new position in shares of Enanta Pharmaceuticals during the third quarter worth approximately $113,000. Finally, State Board of Administration of Florida Retirement System acquired a new position in shares of Enanta Pharmaceuticals in the 1st quarter valued at $118,000. 94.99% of the stock is currently owned by institutional investors and hedge funds.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.